Hyperfine (NASDAQ:HYPR – Get Free Report) and Utah Medical Products (NASDAQ:UTMD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
Earnings & Valuation
This table compares Hyperfine and Utah Medical Products”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hyperfine | $11.40 million | 7.48 | -$35.57 million | ($0.38) | -2.12 |
| Utah Medical Products | $38.52 million | 5.83 | $11.29 million | $3.28 | 21.55 |
Volatility and Risk
Hyperfine has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.
Profitability
This table compares Hyperfine and Utah Medical Products’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hyperfine | -210.75% | -97.88% | -61.81% |
| Utah Medical Products | 29.04% | 8.74% | 8.50% |
Insider and Institutional Ownership
15.0% of Hyperfine shares are held by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 8.0% of Utah Medical Products shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for Hyperfine and Utah Medical Products, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hyperfine | 1 | 1 | 3 | 0 | 2.40 |
| Utah Medical Products | 0 | 1 | 0 | 0 | 2.00 |
Hyperfine currently has a consensus price target of $2.03, suggesting a potential upside of 152.90%. Given Hyperfine’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Hyperfine is more favorable than Utah Medical Products.
Summary
Utah Medical Products beats Hyperfine on 8 of the 14 factors compared between the two stocks.
About Hyperfine
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
About Utah Medical Products
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
